Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “NRAS Mutation”

66 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 66 results

Testing effectiveness (Phase 2)Looking for participantsNCT06970353
What this trial is testing

Phase II Trial of Tunlametinib in NRAS-Mutant Advanced Thyroid Cancer

Who this might be right for
Radioactive Iodine-refractory, Differentiated Thyroid Cancer With NRAS MutationAdvanced PDTC or ATC With NRAS Mutation
Fudan University 40
Not applicableLooking for participantsNCT06449989
What this trial is testing

Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Colorectal Cancer

Who this might be right for
Colorectal Cancer MetastaticBrain Metastases, AdultRas (KRAS or NRAS) Gene Mutation+3 more
Blokhin's Russian Cancer Research Center 30
Early research (Phase 1)Ended earlyNCT06270082
What this trial is testing

Study of IK-595 in RAS- or RAF-altered Advanced Tumors

Who this might be right for
Solid Tumor, AdultColorectal CancerPancreatic Cancer+7 more
Ikena Oncology 75
Early research (Phase 1)Looking for participantsNCT06096974
What this trial is testing

Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS

Who this might be right for
Advanced Solid Tumors
Shanghai YingLi Pharmaceutical Co. Ltd. 60
Testing effectiveness (Phase 2)Looking for participantsNCT06949982
What this trial is testing

Efficacy And Safety Of Hydroxychloroquine Combined With Methotrexate, Capecitabine And Bevacizumab Vs. Regorafenib In Participants With Refractory Metastatic Colorectal Cancer With Mutations In RAS Genes

Who this might be right for
Metastatic Colorectal Cancer (mCRC)Colorectal Neoplasms
Sergey Orlov, MD 60
Not applicableLooking for participantsNCT04151342
What this trial is testing

CAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS)

Who this might be right for
CancerMalignancies MultipleMalignant Solid Tumor+7 more
University Health Network, Toronto 5,500
Testing effectiveness (Phase 2)Study completedNCT05217303
What this trial is testing

HL-085 in NRAS-mutated Advanced Melanoma

Who this might be right for
Melanoma
Shanghai Kechow Pharma, Inc. 100
Early research (Phase 1)Temporarily pausedNCT03932253
What this trial is testing

MEK Inhibitor FCN-159 To Treat Advanced Melanoma With NRAS-aberrant (Ia) and NRAS-mutant (Ib)or NF1-mutant(1b)

Who this might be right for
Melanoma
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. 79
Early research (Phase 1)Study completedNCT02906059
What this trial is testing

Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
NYU Langone Health 7
Not applicableStudy completedNCT03493230
What this trial is testing

Detection of Plasmatic Cell-free BRAF and NRAS Mutations : a New Tool for Monitoring Patients With Metastatic Malignant Melanoma Treated With Targeted Therapies or Immunotherapy ( MALT )

Who this might be right for
Malignant Melanoma Stage IVMalignant Melanoma Stage III
Centre Hospitalier Universitaire de Nice 35
Testing effectiveness (Phase 2)Study completedNCT05593328
What this trial is testing

Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation

Who this might be right for
Colorectal CancerMetastatic Colorectal Cancer
Cardiff Oncology 23
Not applicableStudy completedNCT02827565
What this trial is testing

Technical Optimization of Detection of KRAS, BRAF and NRAS Mutations on Tumor DNA Circulating in Metastatic Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
Institut de Cancérologie de Lorraine 30
Early research (Phase 1)WithdrawnNCT02357732
What this trial is testing

Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib

Who this might be right for
Metastatic Melanoma
University of Pittsburgh
Early research (Phase 1)Looking for participantsNCT06326411
What this trial is testing

Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors

Who this might be right for
OncologyMEK MutationRAF Gene Mutation+6 more
Nested Therapeutics, Inc 230
Large-scale testing (Phase 3)Study completedNCT01763164
What this trial is testing

Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma

Who this might be right for
Metastatic or Unresectable Cutaneous Melanoma
Pfizer 402
Large-scale testing (Phase 3)Looking for participantsNCT07252232
What this trial is testing

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

Who this might be right for
Pancreatic CancerPDACPDAC - Pancreatic Ductal Adenocarcinoma+2 more
Revolution Medicines, Inc. 500
Early research (Phase 1)Looking for participantsNCT04913285
What this trial is testing

Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

Who this might be right for
Solid Tumor, AdultNon-small Cell Lung CancerMelanoma
Pierre Fabre Medicament 400
Testing effectiveness (Phase 2)UnknownNCT03457896
What this trial is testing

Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status

Who this might be right for
Metastatic Colorectal Cancer
NSABP Foundation Inc 35
Testing effectiveness (Phase 2)Temporarily pausedNCT06876142
What this trial is testing

Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma

Who this might be right for
Multiple MyelomaRelapsed and/or Refractory Multiple Myeloma (RRMM)
National Cancer Institute (NCI) 54
Testing effectiveness (Phase 2)Study completedNCT00866177
What this trial is testing

MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma

Who this might be right for
Recurrent MelanomaStage III Skin MelanomaStage IV Skin Melanoma
National Cancer Institute (NCI) 167
Next Page